Sign in

Ted Woo

Research Analyst at Ascendiant Capital Markets

Edward Woo is Director of Research and Senior Analyst at Ascendiant Capital Markets, specializing in equity research with a focus on technology and biotechnology sectors. He covers companies including Cingulate, Alzamend Neuro, Allarity Therapeutics, Aytu BioPharma, and Duos Technologies Group, and has issued high-conviction buy calls such as an 800% return on Quantum Computing Inc. His career spans over twenty years, including prior analyst roles at Wedbush Securities, and he joined Ascendiant in December 2011. Woo is a CFA charterholder, a Yale School of Management MBA, a California licensed CPA (inactive), and holds FINRA Series 7, 16, 24, 63, 86, 87, and 99 registrations.

Ted Woo's questions to DUOS TECHNOLOGIES GROUP (DUOT) leadership

Question · Q1 2025

Inquired about the impact of tariffs and the macroeconomic outlook on the sales cycle for the Edge Data Center and power businesses, and whether customers are delaying signing deals.

Answer

The executive stated that tariffs have not had an impact yet. The power assets are currently in the U.S., and for Edge Data Centers, their agreement with Accu-Tech shields them for now. They have not seen any slowdown in signing deals; both business lines are described as being 'on fire', and they are in a position to prioritize customers.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts